Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Saad Usmani

Saad Usmani

MD, MBBS, MBA, FACP
Memorial Sloan Kettering Cancer Center

Academic History

Saad Usmani MD, MBBS, MBA, FACP, received his medical degree from Allama Iqbal Medical College Lahore, widely regarded as the top medical institution in Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, MI, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, CT. In 2020, Prof. Usmani completed a Masters of Business Administration at UNC Kenan-Flager Business School in Chapel Hill, NC.

Prof. Usmani is Chief of the Myeloma service at the Memorial Sloan Kettering Cancer Center in New York, and is also a member of several professional societies, including the American Society of Hematology (ASH) and the International Myeloma Working Group. He is on the editorial review board of numerous medical journals and has authored/co-authored more than 130 peer-reviewed research manuscripts and 190 abstracts at national and international meetings.

Speaking on imaging and biomarkers in multiple myeloma

Prof. Usmani is a specialist in hematology, medical oncology and bone marrow transplantation. His clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma. Prof. Usmani is interested specifically in the prognostic role of multiple myeloma imaging and identifying mechanisms and biomarkers of resistance to novel agents in high-risk multiple myeloma.

CANDOR results reveal new regimen for RRMM: KdD 6:36
CANDOR results reveal new regimen for RRMM: KdD
Saad Usmani
Immunotherapy in myeloma: current strategies and future perspectives 18:39
Immunotherapy in myeloma: current strategies and future perspectives
Ajai Chari et al. • 12 Sep 2019
6:36
The definitive guide to multiple myeloma at ASH 2018: part V
Mohamad Mohty et al. • 2 Dec 2018
8:25
The definitive guide to multiple myeloma at ASH 2018: part IV
Mohamad Mohty et al. • 2 Dec 2018
3:23
The definitive guide to multiple myeloma at ASH 2018: part III
Mohamad Mohty et al. • 2 Dec 2018
3:33
The definitive guide to multiple myeloma at ASH 2018: part II
Mohamad Mohty et al. • 2 Dec 2018
8:25
The definitive guide to multiple myeloma at ASH 2018: part I
Mohamad Mohty et al. • 2 Dec 2018
Updated POLLUX results for early relapsed myeloma patients 1:24
Updated POLLUX results for early relapsed myeloma patients
Saad Usmani • 5 Oct 2018
Targeting BCMA with bispecific antibodies in R/R myeloma 1:23
Targeting BCMA with bispecific antibodies in R/R myeloma
Saad Usmani • 5 Oct 2018
Monoclonal antibodies: current and future potential 1:35
Monoclonal antibodies: current and future potential
Saad Usmani • 5 Oct 2018
The exciting field of imaging in multiple myeloma 6:48
The exciting field of imaging in multiple myeloma
Jens Hillengass et al. • 18 Oct 2017
Case study: daratumumab in a relapsed patient 3:27
Case study: daratumumab in a relapsed patient
Saad Usmani • 21 Apr 2017
Getting specific with myeloma therapy: selecting the right treatments 1:30
Getting specific with myeloma therapy: selecting the right treatments
Saad Usmani
Navigating advances in the myeloma landscape over the past couple of years 1:59
Navigating advances in the myeloma landscape over the past couple of years
Saad Usmani
Engaging in social media is extremely helpful to discuss research 2:14
Engaging in social media is extremely helpful to discuss research
Saad Usmani • 21 Apr 2017
How can plasma cell leukemia be managed? 4:08
How can plasma cell leukemia be managed?
Saad Usmani • 21 Apr 2017
The content of VJHemOnc is intended for healthcare professionals